Charles S. Berkman
2013 - Ligand Pharmaceuticals
In 2013, Charles S. Berkman earned a total compensation of $731.8K as Vice President and General Counsel at Ligand Pharmaceuticals, a 7% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $113,340 |
|---|---|
| Option Awards | $277,362 |
| Salary | $283,351 |
| Stock Awards | $54,800 |
| Other | $2,908 |
| Total | $731,761 |
Berkman received $283.4K in salary, accounting for 39% of the total pay in 2013.
Berkman also received $113.3K in non-equity incentive plan, $277.4K in option awards, $54.8K in stock awards and $2.9K in other compensation.
Rankings
In 2013, Charles S. Berkman's compensation ranked 7,927th out of 12,286 executives tracked by ExecPay. In other words, Berkman earned more than 35.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,927 out of 12,286 | 36th |
Division Manufacturing | 2,868 out of 4,612 | 38th |
Major group Chemicals And Allied Products | 891 out of 1,462 | 39th |
Industry group Drugs | 674 out of 1,156 | 42nd |
Industry Pharmaceutical Preparations | 535 out of 890 | 40th |
Source: SEC filing on April 12, 2016.
Berkman's colleagues
We found four more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2013.